Related Experiment Video

Updated: Jul 31, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K

[Gene mutation spectrum and clinical characteristics analysis of 178 patients with essential thrombocytosis]

H Dong1, R F Fu, M K Ju

  • 1The State Key Laboratory of Experimental Hematology, Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College.Tianjin Key Laboratory of Gene Therapy for Blood diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin 300020, China.

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|November 29, 2019
PubMed

Insights

Older age and cardiovascular risk factors increase thrombotic events in essential thrombocytosis (ET). CALR mutations offer protection, while age over 60 negatively impacts overall survival in ET patients.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Essential thrombocytosis (ET) is a myeloproliferative neoplasm characterized by elevated platelet counts.
  • Understanding gene mutation spectrum, clinical features, and prognostic factors is crucial for managing ET.
  • Identifying risk factors for disease progression and survival is essential for patient care.

Purpose of the Study:

  • To analyze the gene mutation spectrum (JAK2V617F, CALR, MPL) in ET patients.
  • To investigate clinical features associated with different mutations.
  • To determine factors influencing disease progression (thrombotic events) and overall survival (OS) in ET.

Main Methods:

  • Retrospective analysis of 178 newly diagnosed ET patients.
  • Evaluation of JAK2V617F, CALR, and MPL mutation frequencies.
  • Multivariate analysis to identify risk factors for thrombotic events and OS.

Main Results:

  • CALR mutations were most frequent (40.00%), followed by MPL (25.10%) and JAK2V617F (16.45%).
  • Patients with JAK2V617F mutations showed distinct clinical features compared to CALR mutation carriers.
  • Age >60 years and cardiovascular risk factors (CVF) were significant risk factors for thrombotic events; CALR mutation was protective.
  • Age >60 years was a significant risk factor for overall survival (OS).

Conclusions:

  • Age >60 years and CVF are key risk factors for thrombotic events in ET.
  • CALR mutation demonstrates a protective effect against thrombotic events.
  • Advanced age is a critical determinant of reduced overall survival in ET patients.

Keywords:
Clinical StudyEssential thrombocytosisGene mutation

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...